BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10721779)

  • 1. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
    Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
    Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K; Chizuka A
    Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
    Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
    Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
    Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
    Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.
    Tatsumi M; Sugahara H; Higuchi I; Fukunaga H; Nakamura H; Kanakura Y; Hatazawa J
    Int J Clin Oncol; 2009 Apr; 14(2):150-8. PubMed ID: 19390947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
    Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.
    Fabre-Guillevin E; Tabrizi R; Coulon V; Monnereau A; Eghbali H; Soubeyran I; Soubeyran P
    Leuk Lymphoma; 2006 Apr; 47(4):603-11. PubMed ID: 16690518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
    Xu J; Wang B
    Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
    Kitagawa J; Hara T; Tsurumi H; Goto N; Kanemura N; Yoshikawa T; Kasahara S; Yamada T; Sawada M; Takahashi T; Shimizu M; Takami T; Moriwaki H
    J Cancer Res Clin Oncol; 2009 Jan; 135(1):53-9. PubMed ID: 18592269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
    Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
    Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
    Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
    Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
    Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
    Jo SA; Hwang SH; Chang CL; Kim SY; Shin HJ; Chung JS; Sol MY; Lee EY
    Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
    Shiratori S; Kosugi-Kanaya M; Shigematsu A; Kobayashi H; Yamamoto S; Kobayashi N; Iwasaki H; Mori A; Kunieda Y; Yutaka T; Kurosawa M; Kakinoki Y; Endo T; Kondo T; Hashino S; Teshima T;
    Leuk Lymphoma; 2015; 56(9):2592-7. PubMed ID: 25563559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble interleukin-2 receptor levels in cerebrospinal fluid of patients with acute lymphocytic leukemia or with non-Hodgkin's lymphoma.
    Chang CS; Liu HW; Lin SF; Chen TP
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 May; 22(2):132-7. PubMed ID: 2605973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
    Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
    Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.